TCBP Issues 25% Stock Dividend
TC BioPharm (NASDAQ: TCBP) announced shareholders' approval of a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of January 2, 2025, with delivery expected around January 6th. Trading will temporarily halt from January 2, 2025, at 5:00 pm and resume around January 8, 2025, to process the dividend. Nasdaq will adjust the opening price on January 8 to reflect dilution impact.
CEO Bryan Kobel stated this special dividend reflects management's confidence in the company's financial future and is part of their capital management strategy. He anticipates 2025 to be a period of growth and development, focusing on delivering improved shareholder value.
TC BioPharm (NASDAQ: TCBP) ha annunciato l'approvazione da parte degli azionisti di un dividendo in azioni del 25%. Gli azionisti riceveranno 0,25 American Depositary Shares (ADS) per ogni 1 ADS detenuta a partire dal 2 gennaio 2025, con consegna prevista attorno al 6 gennaio. Le negoziazioni saranno temporaneamente sospese dal 2 gennaio 2025, alle 17:00, e riprenderanno intorno all'8 gennaio 2025, per elaborare il dividendo. Il Nasdaq regolerà il prezzo di apertura dell'8 gennaio per riflettere l'impatto della diluizione.
Il CEO Bryan Kobel ha dichiarato che questo dividendo speciale riflette la fiducia della direzione nel futuro finanziario dell'azienda ed è parte della loro strategia di gestione del capitale. Si attende che il 2025 sia un periodo di crescita e sviluppo, concentrandosi sulla creazione di valore per gli azionisti.
TC BioPharm (NASDAQ: TCBP) anunció la aprobación de los accionistas de un dividendo en acciones del 25%. Los accionistas recibirán 0.25 American Depositary Shares (ADS) por cada 1 ADS que posean a partir del 2 de enero de 2025, con entrega esperada alrededor del 6 de enero. Las negociaciones se suspenderán temporalmente desde el 2 de enero de 2025 a las 5:00 p.m. y se reanudarán alrededor del 8 de enero de 2025 para procesar el dividendo. El Nasdaq ajustará el precio de apertura del 8 de enero para reflejar el impacto de la dilución.
El CEO Bryan Kobel declaró que este dividendo especial refleja la confianza de la dirección en el futuro financiero de la compañía y es parte de su estrategia de gestión del capital. Anticipa que el 2025 será un período de crecimiento y desarrollo, enfocado en ofrecer un mejor valor a los accionistas.
TC BioPharm (NASDAQ: TCBP)는 주주들이 25%의 주식 배당금을 승인했다고 발표했습니다. 주주들은 2025년 1월 2일 현재 보유하고 있는 1 주당 0.25 American Depositary Shares (ADS)를 받을 예정이며, 배달은 1월 6일경으로 예상됩니다. 거래는 2025년 1월 2일 오후 5시부터 임시로 중단되며, 배당금을 처리하기 위해 2025년 1월 8일경에 재개됩니다. 나스닥은 배당금 발행에 따른 희석 영향을 반영하기 위해 1월 8일의 개장 가격을 조정할 것입니다.
CEO 브라이언 코벨은 이번 특별 배당이 회사의 재정적 미래에 대한 경영진의 신뢰를 반영하며, 그들의 자본 관리 전략의 일환이라고 밝혔습니다. 그는 2025년이 성장과 발전의 시기가 될 것이며, 주주 가치를 증대시키는 데 집중할 것이라고 예상하고 있습니다.
TC BioPharm (NASDAQ: TCBP) a annoncé l'approbation par les actionnaires d'un dividende en actions de 25%. Les actionnaires recevront 0,25 American Depositary Shares (ADS) pour chaque 1 ADS détenu à partir du 2 janvier 2025, avec une livraison prévue vers le 6 janvier. La négociation sera temporairement suspendue à partir du 2 janvier 2025 à 17h00 et reprendra vers le 8 janvier 2025 pour traiter le dividende. Le Nasdaq ajustera le prix d'ouverture du 8 janvier pour tenir compte de l'impact de la dilution.
Le PDG Bryan Kobel a déclaré que ce dividende spécial reflète la confiance de la direction dans l'avenir financier de l'entreprise et fait partie de leur stratégie de gestion du capital. Il anticipe que 2025 sera une période de croissance et de développement, axée sur l'amélioration de la valeur pour les actionnaires.
TC BioPharm (NASDAQ: TCBP) gab die Genehmigung der Aktionäre für eine 25%ige Aktiendividende bekannt. Aktionäre erhalten für jede gehaltene 1 American Depositary Share (ADS) ab dem 2. Januar 2025 0,25 ADS, wobei die Lieferung um den 6. Januar erwartet wird. Der Handel wird am 2. Januar 2025 um 17:00 Uhr vorübergehend ausgesetzt und soll etwa am 8. Januar 2025 wieder aufgenommen werden, um die Dividende zu verarbeiten. Die Nasdaq wird den Eröffnungskurs am 8. Januar anpassen, um den Verwässerungseffekt zu berücksichtigen.
CEO Bryan Kobel erklärte, dass diese Sonderdividende das Vertrauen des Managements in die finanzielle Zukunft des Unternehmens widerspiegelt und Teil ihrer Kapitalmanagementstrategie ist. Er erwartet, dass 2025 eine Phase des Wachstums und der Entwicklung sein wird, die sich darauf konzentriert, den Wert für die Aktionäre zu steigern.
- 25% stock dividend approved by shareholders
- Management expresses strong confidence in company's financial future
- Stock dilution effect from dividend distribution
- Trading suspension from January 2-8, 2025
Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders on the record date of January 2, 2025 are expected to be delivered to shareholders on or about January 6th.
TC BioPharm CEO, Bryan Kobel stated: "Rewarding additional shares to shareholders in the form of this special dividend is an important and effective component of our capital management strategy. It also reflects management's strong confidence in the Company's financial future. I anticipate 2025 to be a period of growth and development for our Company as we remain focused on delivering improved value for our shareholders."
Per Nasdaq requirements, trading in the Company's ADSs will temporarily stop at 5:00 pm on January 2, 2025, and recommence on or around January 8, 2025, to allow the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 8 to reflect the dilution impact of the stock dividend.
This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy shares of the Company's common stock or any other securities. For additional information regarding TC BioPharm's General Meeting see our website and filings to be made on form 6K.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html
SOURCE TC BioPharm
FAQ
What is the stock dividend ratio announced by TC BioPharm (TCBP)?
When is the record date for TCBP's stock dividend?
When will TCBP shareholders receive their stock dividend?
How long will TCBP stock trading be suspended for the dividend process?
How will the TCBP stock dividend affect the share price?
